(penicillamine tablets, USP)
Penicillamine is 3-mercapto-D-valine, a disease modifying antirheumatic drug. It is a white or practically white, crystalline powder, freely soluble in water, slightly soluble in alcohol, and insoluble in ether, acetone, benzene, and carbon tetrachloride. Although its configuration is D, it is levorotatory as usually measured.
DEPEN is indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that DEPEN is not of value in ankylosing spondylitis.
Media Articles Related to Depen (Penicillamine)
Opioid Dependence Can Start in Just a Few Days
Source: MedicineNet oxycodone Specialty [2017.03.17]
Title: Opioid Dependence Can Start in Just a Few Days
Category: Health News
Created: 3/16/2017 12:00:00 AM
Last Editorial Review: 3/17/2017 12:00:00 AM
How best to treat infections and tumors: Choice of containment versus aggressive treatment depends on drug resistance
Source: MRSA / Drug Resistance News From Medical News Today [2017.02.09]
In cases where drug resistance can lead to treatment failure, new research shows that therapies tailored to contain an infection or a tumor at tolerable levels can, in some cases, extend the...
Whether Statins Cut Alzheimer's Risk May Depend on Gender, Race
Source: MedicineNet atorvastatin Specialty [2016.12.13]
Title: Whether Statins Cut Alzheimer's Risk May Depend on Gender, Race
Category: Health News
Created: 12/12/2016 12:00:00 AM
Last Editorial Review: 12/13/2016 12:00:00 AM
Empowering people with incontinence and their carers to live independent and dignified lives at home and in the community
Source: Caregivers / Homecare News From Medical News Today [2016.04.27]
Study conducted in six European regions contributes to better understanding of how to improve thecare for people with incontinence in their daily lives at home and in the community.
Inability to work: Medical experts often disagree
Source: Health Insurance / Medical Insurance News From Medical News Today [2017.01.27]
Independent medical evaluations are often used to adjudicate disability claims. But different doctors assessing the same patient often disagree on whether the patient is disabled or not.
Published Studies Related to Depen (Penicillamine)
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.09]
PURPOSE: To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants... CONCLUSION: Prophylactic enterally administered DPA suspension in a dose 100 mg/kg/dose 8 h for 3 days, followed by 50 mg/kg once per day for next 11 days, does not prevent 'any stage ROP or death' or 'ROP requiring treatment' in VLBW infants. DPA is well tolerated and does not have any major short-term adverse effects. (c) 2010 The Author(s)/Journal Compilation (c) 2010 Foundation Acta Paediatrica.
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.04.16]
Abstract Purpose: To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants. Methods: This was a double-blind, single-centre, randomized, placebo-controlled trial with stratification (for birth weight <1250 and >/=1250 g) and blocking...
D-Penicillamine for preventing retinopathy of prematurity in preterm infants. 
CONCLUSIONS: Administration of prophylactic D-penicillamine in preterm
D-penicillamine, a potent melanogenesis inhibitor, lacks any depigmenting effect on black guinea pig skin: the first randomized, evaluator-blinded, vehicle-controlled, in vivo study. [2011.06]
D-penicillamine is a melanogenesis inhibitor. This in vivo study on ten black guinea pigs using a 5% D-penicillamine ointment showed its lack of any skin-lightening effect.The potential reasons for this ineffectiveness are discussed in the paper, which could be very helpful for researchers exploring new skin-lightening agents.
D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. [2011.04.15]
Long term D-penicillamine (DPA) therapy to treat Wilson disease can induce elastosis perforans serpiginosa (EPS), a very rare degenerative skin disease characterized by a transepidermal elimination of elastic fiber aggregates.
Clinical Trials Related to Depen (Penicillamine)
Post Marketing Surveillance Study of Cuprimine [No longer available]
Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a
Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able
to request the drug for their patients from the Sponsor. A Clinical Study Report form was
completed for each purchase of Cuprimine.
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma [Completed]
RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the
tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation
therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be
effective in treating glioblastoma.
PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and
radiation therapy in treating patients who have newly diagnosed glioblastoma.
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine [Not yet recruiting]
A study to review Wilson disease patients who have previously been prescribed d-
Penicillamine but were changed to trientine as treatment for their disease, and to follow
them for a further 12 months.
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria [Recruiting]
The purpose of this study is to evaluate the effect of escalating doses of cystine biding
thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which
is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall
goal will be to help guide therapy and ultimately minimize unnecessary side effects caused
by larger doses.
Cystine Capacity Clinical Study (CysCap) [Recruiting]
The purpose of this study is to determine whether urinary cystine capacity, an assay used to
measure the amount of cystine in the urine, can be used to predict stone recurrence in
patients with cystinuria.